Business Context and Reporting Period
This Form 8-K was filed by Integer Holdings Corporation on April 23, 2019. The report addresses executive leadership changes within the Cardiac Rhythm Management & Neuromodulation (CRM&N) product line.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation:
- Severance Payment: $320,000 in aggregate cash severance for the departing executive.
- Equity and Bonus: Pro-rated eligibility for short-term incentive bonuses and unvested performance-based equity awards.
Material Changes
The primary material change is the departure of Antonio Gonzalez as President of the CRM&N product line, effective immediately. Mr. Gonzalez will remain employed until January 3, 2020, before separating from the company. Concurrently, the company appointed Joel Becker as the new President of the CRM&N product line.
Management Commentary and Outlook
Management stated that Mr. Becker brings nearly 20 years of experience from St. Jude Medical, including leadership of the Americas Division. The company expects Mr. Becker to leverage his industry relationships and product knowledge to build on the CRM&N line's strong performance and execute a strategy for above-market growth.
Investor Verification Checklist
- Confirm the terms of the separation agreement and customary release provisions required for the $320,000 severance.
- Verify the specific performance goals attached to Mr. Gonzalez's pro-rated equity awards.
- Monitor the CRM&N product line's performance metrics in subsequent quarterly reports to assess the impact of the leadership transition.
- Review future filings for any additional executive compensation arrangements related to Mr. Becker's appointment.